<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>lung cancer immunotherapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/lung-cancer-immunotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 23 Oct 2025 10:21:46 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>lung cancer immunotherapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Second-Gen Sequencing in Lung Cancer Immunotherapy</title>
		<link>https://bioengineer.org/second-gen-sequencing-in-lung-cancer-immunotherapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 23 Oct 2025 10:21:41 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[diagnostic applications of mNGS]]></category>
		<category><![CDATA[infection dynamics in cancer immunotherapy]]></category>
		<category><![CDATA[lung cancer immunotherapy]]></category>
		<category><![CDATA[metagenomic next-generation sequencing (mNGS)]]></category>
		<category><![CDATA[opportunistic infections in immunotherapy]]></category>
		<guid isPermaLink="false">https://bioengineer.org/second-gen-sequencing-in-lung-cancer-immunotherapy/</guid>

					<description><![CDATA[The advent of immunotherapy has revolutionized the treatment landscape for lung cancer, offering new hope to patients through harnessing the body’s own immune system to combat tumor cells. However, this evolving frontier carries complexities, especially when patients concurrently suffer from infections. A groundbreaking study recently published in BMC Cancer uncovers how next-generation sequencing technologies can [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">285752</post-id>	</item>
	</channel>
</rss>
